ALT
Altimmune, Inc.
7.60
+
0.17
2.29%
1 x 7.52
1 x 7.67
bid
ask
09:37 AM
timesize
Bearish
41
Bullish
102
sentiment
7.56
day range
7.77
2.09
52 week range
14.84
News
...
Validea Detailed Fundamental Analysis- Nasdaq | news.google.com • |
Understanding ALT’s book value per share for better investment insights | news.google.com • |
Altimmune Inc [ALT] Director sales 16,011 shares for $0.11 million. | news.google.com • |
Altimmune Inc (ALT) can make a big difference with a little luck | news.google.com • |
Los Angeles Capital Management LLC Takes Position in Altimmune, Inc. (NASDAQ:ALT) | news.google.com • |
Altimmune (NASDAQ:ALT) Stock Price Up 9% | news.google.com • |
Profile
...
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.
Earning
...
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-05 | 2024-09 | -0.36 | N/A | N/A | N/A |
2024-08-08 | 2024-06 | -0.34 | -0.35 | -0.01 | -2.94% |
2024-05-09 | 2024-03 | -0.36 | -0.34 | 0.02 | 5.56% |
2024-03-27 | 2023-12 | -0.35 | -0.33 | 0.02 | 5.71% |
2023-11-07 | 2023-09 | -0.4 | -0.39 | 0.01 | 2.50% |
2023-08-10 | 2023-06 | -0.44 | -0.32 | 0.12 | 27.27% |
Upgrade / Downgrade
...
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-08-13 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-08-10 | B. Riley Securities | Upgrade | Buy | Buy |
2023-07-11 | JMP Securities | Upgrade | Market Outperform | Market Outperform |
2023-05-14 | HC Wainwright & Co. | Upgrade | Buy | Buy |
2023-03-30 | JMP Securities | Upgrade | Market Outperform | |
2023-03-21 | JMP Securities | Upgrade | Market Outperform |
Insider Holder
...
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-08-18 | DRUTZ DAVID J | Director | 0.00 | Sale |
2024-01-30 | EISENSTADT RICHARD I | Chief Financial Officer | 45.01K | Stock Award(Grant) |
2024-02-01 | GARG VIPIN K. | Chief Executive Officer | 292.03K | Conversion of Exercise of derivative security |
2022-08-11 | GILL JOHN M | Director | 2.77K | Sale |
2024-07-30 | HARRIS MATTHEW SCOTT | Officer | 55.12K | Stock Award(Grant) |
2024-07-30 | JORDT RAYMOND M | Officer | 14.66K | Stock Award(Grant) |
Institution Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Blackrock Inc. | 3.66M | 12.93M | 6.95% |
2023-06-29 | Nuveen Asset Management, LLC | 3.46M | 12.21M | 6.57% |
2023-06-29 | Vanguard Group Inc | 3.31M | 11.67M | 6.27% |
2023-06-29 | Tang Capital Management, LLC | 2.75M | 9.71M | 5.22% |
2023-06-29 | Marshall Wace LLP | 2.06M | 7.27M | 3.91% |
2023-06-29 | Laurion Capital Management, LP | 1.84M | 6.49M | 3.49% |
Fund Ownership
...
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | College Retirement Equities Fund-Stock Account | 2.00M | 7.05M | 3.79% |
2023-06-29 | Vanguard Total Stock Market Index Fund | 1.62M | 5.71M | 3.07% |
2023-06-29 | College Retirement Equities Fund-Global Equities Account | 1.27M | 4.48M | 2.41% |
2023-08-30 | iShares Russell 2000 ETF | 1.18M | 3.00M | 2.25% |
2023-06-29 | Vanguard Extended Market Index Fund | 621.63K | 2.19M | 1.18% |
2023-06-29 | Vanguard Horizon Fund-Strategic Small-Cap Equity Fund | 490.56K | 1.73M | 0.93% |
Dividend
...
Dividend | Date |
---|---|
291 | 2017-02-07 |
2.91 | 2017-02-06 |
291.003 | 2017-01-20 |
Split
...
Split | Date |
---|---|
1 : 30 | 2018-09-14 |
10 : 1 | 2017-05-05 |
This topic has been deleted. Only users with topic management privileges can see it.
-
lol... you guys are silly...literally nothing is Going to happen. The call will be vague nothingness like every other time...stock will slip back into $1.90s
-
What time is the call?
-
No...it will go down after call
-
Just keep loading and waiting
-
There will be no significance news and we’ll be back under $2 by eod tomorrow...
-
Fake news Russian bots in here now too?
-
Back to red...
-
Who is doing the buying?
-
Who’s buying???
-
So what happens when we all get to even money and everyone starts selling...
-
Tomorrow down 0.19... lol
-
Why is it time to buy?
-
We been hearing that for years S K
-
5500 now!
-
Is that a green I see?
-
It will close red. 1.50
-
Then you’re down 20 bucks...
-
It’ll close 1.52
-
Told you so what?
-
Ilan nobody answers any questions but I don’t think they did
-
Validea Detailed Fundamental Analysis- Nasdaq
news.google.com • -
Understanding ALT’s book value per share for better investment insights
news.google.com • -
Altimmune Inc [ALT] Director sales 16,011 shares for $0.11 million.
news.google.com • -
Altimmune Inc (ALT) can make a big difference with a little luck
news.google.com • -
Altimmune (NASDAQ:ALT) Stock Price Up 9%
news.google.com • -
(ALT) Trading Report
news.google.com • -
Five Top Obesity Stocks to Buy and Hold Long Term
247wallst.com • -
We're Not Very Worried About Altimmune's (NASDAQ:ALT) Cash Burn Rate
news.google.com • -
ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024
accesswire.com • -
Altimmune: Emerging Position In Competitive Space, But Risks Remain
seekingalpha.com • -
ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer
accesswire.com • -
ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024
accesswire.com • -
ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024
accesswire.com • -
3 Promising Biotech Stocks for the Long-Term: August 2024
investorplace.com • -
The 7 Best Under $10 Stocks to Buy in August 2024
investorplace.com • -
Altimmune, Inc. (ALT) Q2 2024 Earnings Call Transcript
seekingalpha.com •